亚洲精品国产成人一区二区_欧美性xxxxx极品娇小_国产欧美久久一区二区三区_日日麻批免费40分钟无码

Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for JUNMAIKANG? (Adalimumab)

Release time:Aug 17, 2022

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of the whole industry chain, announced the acceptance of supplemental biologics license application by China National Medical Products Administration (NMPA) for JUNMAIKANG? (Adalimumab), developed by Mabwell in cooperation with Junshi Biosciences (1877.HK, 688180.SH), for the treatment of Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease.

JUNMAIKANG? has received support from the Major Scientific and Technological Special Project for Significant New Drug Development during China’s Twelfth Five-year Plan Period, and was approved for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in March of this year. In accordance with the supplementary agreement, and sales and promotional services agreement concluded, Mabwell is responsible for the promotion of JUNMAIKANG?, and will be responsible for its production after the completion of the production transfer. The profits will be distributed by Mabwell or Mabwell's subsidiary and Junshi Biosciences at 50%:50%.

主站蜘蛛池模板: 莱西市| 探索| 临西县| 东宁县| 湟源县| 阳城县| 历史| 靖宇县| 阿尔山市| 山阴县| 清远市| 柘荣县| 奉化市| 天峨县| 东阳市| 濮阳县| 南木林县| 芦溪县| 阳朔县| 鄄城县| 沅江市| 巧家县| 丹阳市| 岢岚县| 巴南区| 井冈山市| 辽阳县| 北宁市| 城固县| 青州市| 桃园县| 汾西县| 阿鲁科尔沁旗| 茶陵县| 霍山县| 鄂伦春自治旗| 中阳县| 青岛市| 莒南县| 麦盖提县| 长垣县|